2011
DOI: 10.1200/jco.2011.29.15_suppl.1603
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and pathologic profile of breast cancer in a tertiary cancer center in Saudi Arabia.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…This results in Saudi women in Jizan, undergoing a long referral process to reach a cancer centre, thus experiencing deterioration in their health status, or even death, before accessing cancer services (Abdelhadi , AlShehri et al . ). At present, there are no national BC education and screening programmes in the KSA.…”
Section: Discussionmentioning
confidence: 97%
“…This results in Saudi women in Jizan, undergoing a long referral process to reach a cancer centre, thus experiencing deterioration in their health status, or even death, before accessing cancer services (Abdelhadi , AlShehri et al . ). At present, there are no national BC education and screening programmes in the KSA.…”
Section: Discussionmentioning
confidence: 97%
“…Compared to the Western population, BCs have diverse clinical, pathological and molecular features including early onset, higher tumor grade, higher human epidermal growth factor receptor (HER)2 amplification rate, more aggressive subtypes and a lower rate of luminal subtype, in the GCC population ( 7 9 ). Evidence suggests that approximately 46.2% to 54% of BC patients are diagnosed at advanced disease stage ( 7 , 8 , 10 12 ), 23.3% to 28% are diagnosed with localized tumors while ≤2% with in-situ carcinoma ( 8 , 10 ). In the GCC region, the vast majority of BC cases (82.1% to 93%) have invasive ductal carcinoma (IDC) ( 7 , 8 ), and 19.2% to 29.5% have HER2 overexpression ( 7 , 8 , 12 ), while 14.3% to 26.9% have triple-negative BC (TNBC) ( 7 , 8 ).…”
Section: Introductionmentioning
confidence: 99%
“…Evidence suggests that approximately 46.2% to 54% of BC patients are diagnosed at advanced disease stage ( 7 , 8 , 10 12 ), 23.3% to 28% are diagnosed with localized tumors while ≤2% with in-situ carcinoma ( 8 , 10 ). In the GCC region, the vast majority of BC cases (82.1% to 93%) have invasive ductal carcinoma (IDC) ( 7 , 8 ), and 19.2% to 29.5% have HER2 overexpression ( 7 , 8 , 12 ), while 14.3% to 26.9% have triple-negative BC (TNBC) ( 7 , 8 ). The average age of patients at the presentation of BC is at least a decade younger in the GCC population compared to the Western population (<48 years vs 60 years) ( 7 , 13 ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation